Co-Enzyme Q10 Injection solution

Co-Enzyme Q10 Injection solution

Available presentation(s): 5, 20, 50 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: Coenzyme Q10 (ubiquinone/ubiquinol) is a lipid-soluble component of the mitochondrial electron-transport chain. Evidence for parenteral intramuscular use is limited, and no standard compounded IM indication or regimen is established.

Dosage: No validated standard dose or frequency exists for compounded 20 mg/mL intramuscular CoQ10. Any prescription must specify the clinical indication, exact dose, injection volume, frequency, duration and review criteria. Large IM volumes should be divided or avoided according to clinical practice and product-specific instructions.

Mechanisms of Action: Transfers electrons between complexes I/II and III in mitochondria and acts as a membrane antioxidant. Clinical benefit from parenteral administration has not been established for general fatigue or wellness.

Contraindications & Precautions: Avoid in hypersensitivity. Use caution in hepatic disease, bleeding disorders and before surgery. Oil/solubiliser excipients may affect tolerability; verify the full formulation and route suitability.

Interactions: May reduce warfarin effect; monitor INR if used together. Additive blood-pressure or glucose-lowering effects are possible. Oncology use should be agreed with the treating team.

Adverse Reactions / Side Effects: Injection-site pain, induration, erythema, nausea, gastrointestinal upset, headache, dizziness, rash and hypersensitivity are possible; parenteral frequency data are sparse.

Pregnancy & Breastfeeding: Insufficient data support intramuscular use during pregnancy or breastfeeding. Avoid unless a specialist identifies a compelling indication.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• NIH Office of Dietary Supplements. Health Professional Fact Sheets (vitamins and minerals), current online editions. https://ods.od.nih.gov/factsheets/list-VitaminsMinerals/
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers